Appointment of Tucker Kelly as Chief Financial Officer
Tucker Kelly, '96, has been appointed as the Chief Financial Officer (CFO) of Xenon Pharmaceuticals, a neuroscience-focused biopharmaceutical company.
Xenon Pharmaceuticals is dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
Tucker brings outstanding operational experience, having successfully helped lead an organization through the transition to becoming a commercial company.
Kelly brings extensive strategic and commercial finance expertise, both in the U.S. and internationally, to help prepare the company for the anticipated commercialization of its lead candidate, azetukalner.
- Azetukalner is being studied in three Phase 3 programs for the treatment of:
- Epilepsy
- Major depressive disorder (MDD)
- Bipolar depression (BPD)
Author's summary: Tucker Kelly appointed as CFO of Xenon Pharmaceuticals.
More News
- Hemab closes $157m in funding for bleeding disorder treatments
- Would you board an AI-piloted airliner?
- Shimano bike-related sales up 5% through three quarters, but operating income slumps
- Cisco and G42 Deepen US-UAE Technology Partnership to Build Secure, End-to-End AI Infrastructure in the UAE
- Cloud's new performance leader: Arm beats x86
- New HUNT Proven Trail Carbon Wheels On Test
- America Must Innovate to Counter China's Military Advancements
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- 2025 Taiwan Scholarship and Huayu Enrichment Scholarship Recipients' Orientation and Welcome Party - Embarking on a New Journey of Mandarin Learning and Academic Pursuits | AAP
- Research ICT Africa develops AI framework for Africa